Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy
NCT07310186
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
OTHER:
observational study
Sponsor
Peking Union Medical College Hospital